Proposed Data Collection Submitted for Public Comment and Recommendations, 10853-10855 [2018-05000]

Download as PDF Federal Register / Vol. 83, No. 49 / Tuesday, March 13, 2018 / Notices Basswood Partners, LLC, Basswood Enhanced Long Short GP, LLC, and Basswood Capital Management, LLC; all of New York, New York; to retain and acquire voting shares of American River Bankshares, Rancho Cordova, California, and thereby indirectly retain and acquire shares of American River Bank, Sacramento, California. Board of Governors of the Federal Reserve System, March 7, 2018. Ann E. Misback, Secretary of the Board. BILLING CODE P amozie on DSK30RV082PROD with NOTICES Formations of, Acquisitions by, and Mergers of Bank Holding Companies DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 10, 2018. A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001: 1. RCB Holding Company, Inc., Claremore, Oklahoma; to acquire 100 percent of the voting shares of Central Bank and Trust Co., Hutchinson, Kansas. Jkt 244001 BILLING CODE P Proposed Data Collection Submitted for Public Comment and Recommendations FEDERAL RESERVE SYSTEM 17:47 Mar 12, 2018 [FR Doc. 2018–05010 Filed 3–12–18; 8:45 am] [60Day–2018–1091; Docket No. CDC–2018– 0022] [FR Doc. 2018–04953 Filed 3–12–18; 8:45 am] VerDate Sep<11>2014 Board of Governors of the Federal Reserve System, March 8, 2018. Ann E. Misback, Secretary of the Board. The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled ’’Using Qualitative Methods to Understand Issues in HIV Prevention, Care and Treatment in the United States.’’ CDC’s goal for this generic information collection mechanism is to conduct qualitative studies to quickly identify barriers and facilitators to HIV prevention, care and treatment in specific regions with high HIV burden in the US. DATES: CDC must receive written comments on or before May 14, 2018. ADDRESSES: You may submit comments, identified by Docket No. CDC–2018– 0022 by any of the following methods: • Federal eRulemaking Portal: Regulations.gov. Follow the instructions for submitting comments. • Mail: Leroy A. Richardson, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS– D74, Atlanta, Georgia 30329. Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to Regulations.gov. SUMMARY: Please note: Submit all comments through the Federal eRulemaking portal (regulations.gov) or by U.S. mail to the address listed above. PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 10853 To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Leroy A. Richardson, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MS–D74, Atlanta, Georgia 30329; phone: 404–639–7570; Email: omb@cdc.gov. SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below. The OMB is particularly interested in comments that will help: 1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; 2. Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; 3. Enhance the quality, utility, and clarity of the information to be collected; and 4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses. 5. Assess information collection costs. FOR FURTHER INFORMATION CONTACT: Proposed Project Using Qualitative Methods to Understand Issues in HIV Prevention, Care and Treatment in the United States (OMB Control Number 0920–1091; expires 12/31/2018)—Extension— National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). E:\FR\FM\13MRN1.SGM 13MRN1 10854 Federal Register / Vol. 83, No. 49 / Tuesday, March 13, 2018 / Notices Background and Brief Description The CDC’s National Center on HIV/ AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP), Division of HIV/AIDS Prevention (DHAP) seeks a three–year extension to conduct qualitative studies to quickly identify barriers and facilitators to HIV prevention, care and treatment in specific regions with high HIV burden in the US. Proposed activities remain consistent with the national HIV prevention goals, the CDC Division of HIV/AIDS Prevention (DHAP) Strategic Plan, and DHAP’s High-impact HIV Prevention approach. The purposes for each data collection study supported under this umbrella generic information collection plan will be to understand specific barriers and facilitators to local HIV prevention, care and treatment in the United States and territories. For example, each study will seek to identify ways to improve programmatic activities along the continuum of HIV prevention, treatment and care for different populations residing in different geographic settings with greatest burden of HIV. The target populations for the studies include, but are not limited to: (1) Persons living with HIV who are in treatment; (2) persons living with HIV who are out of treatment and who may or may not be seeking treatment at healthcare facilities; (3) persons at high risk for HIV acquisition (HIV negative) and HIV transmission (HIV positive); (4) persons from groups at high risk for HIV including gay, bisexual and other MSM, transgender persons, and injection and non-injection drug users; (5) persons from racial and ethnic minorities; and (6) healthcare providers or other professionals who provide HIV prevention, care and treatment services. Other populations may include individuals who provide non-HIV services or otherwise interact with persons living with HIV or persons at risk for HIV acquisition. Studies will only provide local contextual information about the barriers and facilitators to HIV prevention, care, and treatment experienced by specific communities at risk for acquiring HIV infection, by HIVpositive persons across the HIV care continuum, and by organizations or individuals providing HIV prevention, care, treatment, and related support services. Data collection methods used in any of the specific studies primarily will consist of rapid qualitative assessment methodologies, such as semi-structured and in-depth qualitative interviews, focus groups; direct observations; document reviews; and short structured surveys. Data will be analyzed using well-established qualitative analysis methods, such as coding interviews for themes about barriers and successes to HIV prevention, care, and treatment. Structured response surveys will be analyzed using descriptive statistics and other appropriate statistical methods. CDC will use the results from each specific data collection study to help identify ways to improve local programmatic activities for specific communities along the continuum of HIV prevention, treatment and care for populations and areas with the greatest HIV burden. CDC will communicate study outcomes to local stakeholders and organizations in positions to consider and implement site-specific Type of respondents Public—Adults Public—Adults Public—Adults Public—Adults Public—Adults Public—Adults Public—Adults Average burden per response (in hours) Number of responses per respondent Total burden (in hours) ..................... ..................... ..................... ..................... ..................... ..................... ..................... Study Screener ................................ Contact Information Form ................ Consent Form .................................. Demographic Survey ........................ Interview Guide ................................ Provider Demographic Survey ......... Provider Interview Guide .................. 1,600 600 600 500 500 100 100 1 1 1 1 1 1 1 5/60 1/60 5/60 15/60 1 15/60 45/60 133 10 50 125 500 25 75 Total ........................................... amozie on DSK30RV082PROD with NOTICES General General General General General General General Number of respondents Form name improvements in HIV prevention, care, and treatment for each of the study sites examined. For stakeholders, organizations, or agencies outside the local affected communities, all communications will include clear discussion of the limitations of the region-specific, qualitative methods and the non-generalizability of the study outcomes. For a given year, each separate data collection will range from 30 (minimum) to 200 (maximum) respondents, based on the nature and scope of the research purposes. For example, if there are three data collections, the maximum combined number of expected respondents is 600. In a given year, CDC anticipates the need to screen 1,600 persons to identify 800 eligible persons, of which 600 persons will agree to participate. CDC anticipates that screener forms will take 5 minutes to complete each, contact information forms will take 1 minute to complete each, and consent forms will take 5 minutes to complete each. CDC anticipates study eligibility for 50 percent of the targeted populations screened. Of eligible persons, 75% will agree to participate. Brief structured surveys will take 15 minutes to complete. In-depth interviews or focus groups with respondents are expected to take 60 minutes (1 hour) to complete. In-depth interviews or focus groups with healthcare providers are expected to take 45 minutes to complete. The total annual response burden, based on an average of 600 study respondents per year (assuming three large data collections involving 200 participants each), is 918 hours. ........................................................... ........................ ........................ ........................ 918 VerDate Sep<11>2014 17:47 Mar 12, 2018 Jkt 244001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\13MRN1.SGM 13MRN1 Federal Register / Vol. 83, No. 49 / Tuesday, March 13, 2018 / Notices Leroy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2018–05000 Filed 3–12–18; 8:45 am] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Utilization of Adequate Provision Among Low to Non-Internet Users BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Food and Drug Administration [Docket No. FDA–2017–N–0493] AGENCY: ACTION: [CDC–2017–0114; Docket Number NIOSH– 305] Final National Occupational Research Agenda for Transportation, Warehousing and Utilities National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). AGENCY: ACTION: Notice of availability. NIOSH announces the availability of the final National Occupational Research Agenda for Transportation, Warehousing and Utilities SUMMARY: The final document was published on March 7, 2018. DATES: The document may be obtained at the following link: https:// www.cdc.gov/niosh/nora/sectors/twu/ agenda.html ADDRESSES: FOR FURTHER INFORMATION CONTACT: Emily Novicki, M.A., M.P.H, (NORACoordinator@cdc.gov), National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Mailstop E–20, 1600 Clifton Road NE, Atlanta, GA 30329, phone (404) 498–2581 (not a toll free number). On December 1, 2017, NIOSH published a request for public review in the Federal Register [82 FR 56973] of the draft version of the National Occupational Research Agenda for Transportation, Warehousing and Utilities. No comments were received. amozie on DSK30RV082PROD with NOTICES SUPPLEMENTARY INFORMATION: Dated: March 8, 2018. Frank Hearl, Chief of Staff, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. [FR Doc. 2018–04988 Filed 3–12–18; 8:45 am] BILLING CODE 4163–19–P VerDate Sep<11>2014 17:47 Mar 12, 2018 Jkt 244001 Food and Drug Administration, HHS. Notice. The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Submit either electronic or written comments on the collection of information by April 12, 2018. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202– 395–7285, or emailed to oira_ submission@omb.eop.gov. All comments should be identified with the OMB control number 0910-New and title ‘‘Utilization of Adequate Provision Among Low to Non-internet Users.’’ Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRAStaff@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: SUMMARY: I. Background In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Utilization of Adequate Provision Among Low to Non-Internet Users OMB Control Number 0910–NEW Section 1701(a)(4) of the Public Health Service Act (42 U.S.C. 300u(a)(4)) authorizes FDA to conduct research relating to health information. Section 1003(d)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 393(d)(2)(C)) authorizes FDA to conduct research relating to PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 10855 drugs and other FDA regulated products in carrying out the provisions of the FD&C Act. Prescription drug advertising regulations require that broadcast advertisements containing product claims present the product’s major side effects and contraindications in either audio or audio and visual parts of the advertisement (21 CFR 202.1(e)(1)); this is often called the major statement. The regulations also require that broadcast advertisements contain a brief summary of all necessary information related to side effects and contraindications or that ‘‘adequate provision’’ be made for dissemination of the approved package labeling in connection with the broadcast (§ 202.1(e)(1)). The requirement for adequate provision is generally fulfilled when a firm gives consumers the option of obtaining FDArequired labeling or other information via a toll-free telephone number, through print advertisements or product brochures, through information disseminated at health care provider offices or pharmacies, and through the internet (Ref. 1). The purpose of including all four elements is to ensure that most of a potentially diverse audience can access the information. Internet accessibility is increasing, but many members of certain demographic groups (e.g., older adults, low socioeconomic status individuals) nonetheless report that the internet is inaccessible to them either as a resource or due to limited knowledge, and so a website alone may not adequately serve all potential audiences (Refs. 2 and 3). Similarly, some consumers may prefer to consult sources other than a health care provider to conduct initial research, for privacy reasons or otherwise (Refs. 1, 4, and 5). In light of these considerations, the toll-free number and print ad may provide special value to consumers who are low to non-internet users and/or those who value privacy when conducting initial research on a medication, though not necessarily unique value relative to one another. As such, a primary purpose of this research is to examine the value of including both the toll-free number and print ad as part of adequate provision in direct-to-consumer (DTC) prescription drug broadcast ads. We will also investigate the ability and willingness of low to non-internet users to make use of internet resources if other options were unavailable. These questions will be assessed using a survey methodology administered via telephone. In addition, building on concurrent FDA research regarding drug risk E:\FR\FM\13MRN1.SGM 13MRN1

Agencies

[Federal Register Volume 83, Number 49 (Tuesday, March 13, 2018)]
[Notices]
[Pages 10853-10855]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-05000]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-2018-1091; Docket No. CDC-2018-0022]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part 
of its continuing effort to reduce public burden and maximize the 
utility of government information, invites the general public and other 
Federal agencies the opportunity to comment on a proposed and/or 
continuing information collection, as required by the Paperwork 
Reduction Act of 1995. This notice invites comment on a proposed 
information collection project titled ''Using Qualitative Methods to 
Understand Issues in HIV Prevention, Care and Treatment in the United 
States.'' CDC's goal for this generic information collection mechanism 
is to conduct qualitative studies to quickly identify barriers and 
facilitators to HIV prevention, care and treatment in specific regions 
with high HIV burden in the US.

DATES: CDC must receive written comments on or before May 14, 2018.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2018-
0022 by any of the following methods:
     Federal eRulemaking Portal: Regulations.gov. Follow the 
instructions for submitting comments.
     Mail: Leroy A. Richardson, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, MS-D74, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. CDC will post, without change, all relevant comments 
to Regulations.gov.

    Please note:  Submit all comments through the Federal 
eRulemaking portal (regulations.gov) or by U.S. mail to the address 
listed above.


FOR FURTHER INFORMATION CONTACT:  To request more information on the 
proposed project or to obtain a copy of the information collection plan 
and instruments, contact Leroy A. Richardson, Information Collection 
Review Office, Centers for Disease Control and Prevention, 1600 Clifton 
Road, NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: 
    Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-
3520), Federal agencies must obtain approval from the Office of 
Management and Budget (OMB) for each collection of information they 
conduct or sponsor. In addition, the PRA also requires Federal agencies 
to provide a 60-day notice in the Federal Register concerning each 
proposed collection of information, including each new proposed 
collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to the OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    The OMB is particularly interested in comments that will help:
    1. Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    2. Evaluate the accuracy of the agency's estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    3. Enhance the quality, utility, and clarity of the information to 
be collected; and
    4. Minimize the burden of the collection of information on those 
who are to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submissions of responses.
    5. Assess information collection costs.

Proposed Project

    Using Qualitative Methods to Understand Issues in HIV Prevention, 
Care and Treatment in the United States (OMB Control Number 0920-1091; 
expires 12/31/2018)--Extension--National Center for HIV/AIDS, Viral 
Hepatitis, STD, and TB Prevention, Centers for Disease Control and 
Prevention (CDC).

[[Page 10854]]

Background and Brief Description

    The CDC's National Center on HIV/AIDS, Viral Hepatitis, STD and TB 
Prevention (NCHHSTP), Division of HIV/AIDS Prevention (DHAP) seeks a 
three-year extension to conduct qualitative studies to quickly identify 
barriers and facilitators to HIV prevention, care and treatment in 
specific regions with high HIV burden in the US. Proposed activities 
remain consistent with the national HIV prevention goals, the CDC 
Division of HIV/AIDS Prevention (DHAP) Strategic Plan, and DHAP's High-
impact HIV Prevention approach.
    The purposes for each data collection study supported under this 
umbrella generic information collection plan will be to understand 
specific barriers and facilitators to local HIV prevention, care and 
treatment in the United States and territories. For example, each study 
will seek to identify ways to improve programmatic activities along the 
continuum of HIV prevention, treatment and care for different 
populations residing in different geographic settings with greatest 
burden of HIV.
    The target populations for the studies include, but are not limited 
to: (1) Persons living with HIV who are in treatment; (2) persons 
living with HIV who are out of treatment and who may or may not be 
seeking treatment at healthcare facilities; (3) persons at high risk 
for HIV acquisition (HIV negative) and HIV transmission (HIV positive); 
(4) persons from groups at high risk for HIV including gay, bisexual 
and other MSM, transgender persons, and injection and non-injection 
drug users; (5) persons from racial and ethnic minorities; and (6) 
healthcare providers or other professionals who provide HIV prevention, 
care and treatment services. Other populations may include individuals 
who provide non-HIV services or otherwise interact with persons living 
with HIV or persons at risk for HIV acquisition.
    Studies will only provide local contextual information about the 
barriers and facilitators to HIV prevention, care, and treatment 
experienced by specific communities at risk for acquiring HIV 
infection, by HIV-positive persons across the HIV care continuum, and 
by organizations or individuals providing HIV prevention, care, 
treatment, and related support services.
    Data collection methods used in any of the specific studies 
primarily will consist of rapid qualitative assessment methodologies, 
such as semi-structured and in-depth qualitative interviews, focus 
groups; direct observations; document reviews; and short structured 
surveys. Data will be analyzed using well-established qualitative 
analysis methods, such as coding interviews for themes about barriers 
and successes to HIV prevention, care, and treatment. Structured 
response surveys will be analyzed using descriptive statistics and 
other appropriate statistical methods.
    CDC will use the results from each specific data collection study 
to help identify ways to improve local programmatic activities for 
specific communities along the continuum of HIV prevention, treatment 
and care for populations and areas with the greatest HIV burden. CDC 
will communicate study outcomes to local stakeholders and organizations 
in positions to consider and implement site-specific improvements in 
HIV prevention, care, and treatment for each of the study sites 
examined. For stakeholders, organizations, or agencies outside the 
local affected communities, all communications will include clear 
discussion of the limitations of the region-specific, qualitative 
methods and the non-generalizability of the study outcomes.
    For a given year, each separate data collection will range from 30 
(minimum) to 200 (maximum) respondents, based on the nature and scope 
of the research purposes. For example, if there are three data 
collections, the maximum combined number of expected respondents is 
600. In a given year, CDC anticipates the need to screen 1,600 persons 
to identify 800 eligible persons, of which 600 persons will agree to 
participate.
    CDC anticipates that screener forms will take 5 minutes to complete 
each, contact information forms will take 1 minute to complete each, 
and consent forms will take 5 minutes to complete each. CDC anticipates 
study eligibility for 50 percent of the targeted populations screened. 
Of eligible persons, 75% will agree to participate.
    Brief structured surveys will take 15 minutes to complete. In-depth 
interviews or focus groups with respondents are expected to take 60 
minutes (1 hour) to complete. In-depth interviews or focus groups with 
healthcare providers are expected to take 45 minutes to complete.
    The total annual response burden, based on an average of 600 study 
respondents per year (assuming three large data collections involving 
200 participants each), is 918 hours.

----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
      Type of respondents           Form name        Number of     responses per   per response    Total burden
                                                    respondents     respondent      (in hours)      (in hours)
----------------------------------------------------------------------------------------------------------------
General Public--Adults........  Study Screener..           1,600               1            5/60             133
General Public--Adults........  Contact                      600               1            1/60              10
                                 Information
                                 Form.
General Public--Adults........  Consent Form....             600               1            5/60              50
General Public--Adults........  Demographic                  500               1           15/60             125
                                 Survey.
General Public--Adults........  Interview Guide.             500               1               1             500
General Public--Adults........  Provider                     100               1           15/60              25
                                 Demographic
                                 Survey.
General Public--Adults........  Provider                     100               1           45/60              75
                                 Interview Guide.
                                                                                                 ---------------
    Total.....................  ................  ..............  ..............  ..............             918
----------------------------------------------------------------------------------------------------------------



[[Page 10855]]

Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific 
Integrity, Office of the Associate Director for Science, Office of the 
Director, Centers for Disease Control and Prevention.
[FR Doc. 2018-05000 Filed 3-12-18; 8:45 am]
 BILLING CODE 4163-18-P